Scholarlink

Aim <p>The MiniMed™ 780G system utilizes an Advanced Hybrid Closed-Loop algorithm, which is optimized to perform best at a glucose target of 100&#xa0;mg/dL. The system also includes a temporary target feature (TT) of 150&#xa0;mg/dL that can be set when higher glucose utilization is anticipated (e.g., exercise/strenuous work).</p> Methods <p>Real-world data from 1002 randomly selected users of the MiniMed™ 780G and MiniMed™ 670G systems were used to investigate the TT functionality (n = 501 MiniMed™ 780G users, n = 501 MiniMed™ 670G users). Continuous glucose monitoring (CGM) metrics were calculated for 4-h intervals (4&#xa0;h prior to commencing TT use and 0–4, 4–8, 8–12, 12–16, 16–20 and 20–24&#xa0;h after TT initiation).</p> Results <p>CGM results showed that, with both systems, the time-in-range (TIR) during TT periods mostly equalled or exceeded TIR in corresponding non-TT periods. In the first 4&#xa0;h after TT initiation, the MiniMed™ 780G system demonstrated a TIR and time in tight range (TITR) of 71.6% and 46.4%, respectively, [a 1.6 (p = 0.11) and 2.6 (p = 0.009) percentage point benefit in TIR and TITR, respectively, versus the 670G system]. Mean time-below-range remained below target in both periods.</p> Conclusions <p>These findings confirm that the TT setting performs as intended, allowing users to maintain TIR during strenuous activity without compromising safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Use of the temporary glycemic target feature in the medtronic MiniMed™ 780G advanced hybrid closed loop system: a real-world evidence study

  • 期刊论文

  • 发表日期：

    2025年6月5日

查看全文
  • Jeremy Basset-Sagarminaga,
  • Tim van den Heuvel,
  • Javier Castañeda,
  • Ohad Cohen

摘要

Aim

The MiniMed™ 780G system utilizes an Advanced Hybrid Closed-Loop algorithm, which is optimized to perform best at a glucose target of 100 mg/dL. The system also includes a temporary target feature (TT) of 150 mg/dL that can be set when higher glucose utilization is anticipated (e.g., exercise/strenuous work).

Methods

Real-world data from 1002 randomly selected users of the MiniMed™ 780G and MiniMed™ 670G systems were used to investigate the TT functionality (n = 501 MiniMed™ 780G users, n = 501 MiniMed™ 670G users). Continuous glucose monitoring (CGM) metrics were calculated for 4-h intervals (4 h prior to commencing TT use and 0–4, 4–8, 8–12, 12–16, 16–20 and 20–24 h after TT initiation).

Results

CGM results showed that, with both systems, the time-in-range (TIR) during TT periods mostly equalled or exceeded TIR in corresponding non-TT periods. In the first 4 h after TT initiation, the MiniMed™ 780G system demonstrated a TIR and time in tight range (TITR) of 71.6% and 46.4%, respectively, [a 1.6 (p = 0.11) and 2.6 (p = 0.009) percentage point benefit in TIR and TITR, respectively, versus the 670G system]. Mean time-below-range remained below target in both periods.

Conclusions

These findings confirm that the TT setting performs as intended, allowing users to maintain TIR during strenuous activity without compromising safety.